In efforts to bring as many unit dose generics to the market as possible, AvKARE recently launched a handful of new medications, including Clopidogrel.  

Clopidogrel, also known as Plavix, is an anti-platelet medication that prevents blood clots from forming.  This drug is predominantly prescribed to patients with heart disease or blood circulation disease who are at risk for myocardial infarction and strokes. Clopidogrel may also be prescribed to patients who suffer from atrial fibrillation.  This drug works by binding to the P2Y12 receptor on platelets, which inhibits adenosine diphosphate (ADP) from stimulating the platelets, essentially, blocking platelets from sticking together and forming blood clots.

In order to work effectively, Clopidogrel must be metabolized and changed to its active form.  Some patients are unable to metabolize the drug; thus, it is an ineffective treatment compared to those who can.

Clopidogrel can be taken in conjunction with aspirin, however, this combination does increase the risk of gastrointestinal bleeding by just 1%.  According to, “The CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial showed that the addition of Clopidogrel to aspirin therapy reduced the incidence of cardiovascular death, MI, or stroke from 11.4% to 9.3%…”  This drug should not be taken in conjunction with Omeprazole or Esomeprazole, as they significantly reduce Clopidogrel’s effectiveness.  Opioids are also contraindicated, as they reduce the body’s absorption of Clopidogrel. 

Clopidogrel is also used to treat unstable angina and to reduce the likelihood of recurrent events. We hope this medication can be used in the unit dose form to enhance the health and wellbeing of patients across the nation!